510 related articles for article (PubMed ID: 18502028)
1. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Lazzeri M
Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027
[No Abstract] [Full Text] [Related]
4. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Novara G
Eur Urol; 2009 Mar; 55(3):737. PubMed ID: 18502023
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
[TBL] [Abstract][Full Text] [Related]
8. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
9. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine].
Dorschner W; Stolzenburg JU; Griebenow R; Halaska M; Brünjes R; Frank M; Wieners F
Aktuelle Urol; 2003 Mar; 34(2):102-8. PubMed ID: 14566693
[TBL] [Abstract][Full Text] [Related]
10. Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009;55:729-38.
Ates F; Akyol I; Cirakoglu A
Eur Urol; 2009 Jul; 56(1):e1; author reply e2. PubMed ID: 19056165
[No Abstract] [Full Text] [Related]
11. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
[TBL] [Abstract][Full Text] [Related]
12. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Martínez-García R; Abadías M; Arañó P; Perales L; Ruíz JL; Sust M; Conejero J;
Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
14. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
15. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
Jünemann KP; Halaska M; Rittstein T; Mürtz G; Schnabel F; Brünjes R; Nurkiewicz W
Eur Urol; 2005 Sep; 48(3):478-82. PubMed ID: 15967567
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
18. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
19. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
20. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
